Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Lorelei Ann Mucci, Sc.D.

Co-Author

This page shows the publications co-authored by Lorelei Mucci and Meir Stampfer.
Connection Strength

8.283
  1. Mounting evidence for prediagnostic use of statins in reducing risk of lethal prostate cancer. J Clin Oncol. 2014 Jan 01; 32(1):1-2.
    View in: PubMed
    Score: 0.582
  2. Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):1086-1093.
    View in: PubMed
    Score: 0.220
  3. Aspirin Use and Lethal Prostate Cancer in the Health Professionals Follow-up Study. Eur Urol Oncol. 2019 03; 2(2):126-134.
    View in: PubMed
    Score: 0.201
  4. Pineal Gland Volume Assessed by MRI and Its Correlation with 6-Sulfatoxymelatonin Levels among Older Men. J Biol Rhythms. 2016 10; 31(5):461-9.
    View in: PubMed
    Score: 0.175
  5. Sleep Duration and Disruption and Prostate Cancer Risk: a 23-Year Prospective Study. Cancer Epidemiol Biomarkers Prev. 2016 Feb; 25(2):302-8.
    View in: PubMed
    Score: 0.168
  6. Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC. Prostate. 2015 Dec; 75(16):1926-33.
    View in: PubMed
    Score: 0.165
  7. Physical Activity and Prostate Tumor Vessel Morphology: Data from the Health Professionals Follow-up Study. Cancer Prev Res (Phila). 2015 Oct; 8(10):962-967.
    View in: PubMed
    Score: 0.164
  8. GermLine Variation in Superoxide Dismutase-2 (SOD2) and Survival Outcomes After Radiation Therapy for Prostate Cancer: Results of a Test and Validation Set Analysis. Clin Genitourin Cancer. 2015 Aug; 13(4):370-377.e1.
    View in: PubMed
    Score: 0.157
  9. Circadian clock genes and risk of fatal prostate cancer. Cancer Causes Control. 2015 Jan; 26(1):25-33.
    View in: PubMed
    Score: 0.156
  10. Association of prostate cancer risk variants with gene expression in normal and tumor tissue. Cancer Epidemiol Biomarkers Prev. 2015 Jan; 24(1):255-60.
    View in: PubMed
    Score: 0.155
  11. Vasectomy and risk of aggressive prostate cancer: a 24-year follow-up study. J Clin Oncol. 2014 Sep 20; 32(27):3033-8.
    View in: PubMed
    Score: 0.154
  12. Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men. Eur Urol. 2015 Feb; 67(2):191-4.
    View in: PubMed
    Score: 0.153
  13. Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2014 Oct; 23(10):2027-31.
    View in: PubMed
    Score: 0.151
  14. Genetic variation across C-reactive protein and risk of prostate cancer. Prostate. 2014 Jul; 74(10):1034-42.
    View in: PubMed
    Score: 0.151
  15. SPINK1 protein expression and prostate cancer progression. Clin Cancer Res. 2014 Sep 15; 20(18):4904-11.
    View in: PubMed
    Score: 0.149
  16. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J Natl Cancer Inst. 2013 Dec 18; 105(24):1881-90.
    View in: PubMed
    Score: 0.146
  17. Total antioxidant intake in relation to prostate cancer incidence in the Health Professionals Follow-Up Study. Int J Cancer. 2014 Mar 01; 134(5):1156-65.
    View in: PubMed
    Score: 0.145
  18. Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev. 2013 Dec; 22(12):2354-63.
    View in: PubMed
    Score: 0.144
  19. A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer. Clin Cancer Res. 2013 Mar 15; 19(6):1612-9.
    View in: PubMed
    Score: 0.138
  20. Prediagnostic circulating sex hormones are not associated with mortality for men with prostate cancer. Eur Urol. 2014 Apr; 65(4):683-9.
    View in: PubMed
    Score: 0.137
  21. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012 Sep; 21(9):1497-509.
    View in: PubMed
    Score: 0.132
  22. Seasonal variation in expression of markers in the vitamin D pathway in prostate tissue. Cancer Causes Control. 2012 Aug; 23(8):1359-66.
    View in: PubMed
    Score: 0.132
  23. Beta-carotene antioxidant use during radiation therapy and prostate cancer outcome in the Physicians' Health Study. Int J Radiat Oncol Biol Phys. 2012 May 01; 83(1):28-32.
    View in: PubMed
    Score: 0.126
  24. Dietary acrylamide and risk of prostate cancer. Int J Cancer. 2012 Jul 15; 131(2):479-87.
    View in: PubMed
    Score: 0.125
  25. Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study. J Natl Cancer Inst. 2011 Jun 08; 103(11):876-84.
    View in: PubMed
    Score: 0.122
  26. Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality. Prostate. 2012 Feb 01; 72(2):209-16.
    View in: PubMed
    Score: 0.122
  27. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol. 2011 Jun 10; 29(17):2391-6.
    View in: PubMed
    Score: 0.122
  28. Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis. 2010 Sep; 31(9):1597-603.
    View in: PubMed
    Score: 0.115
  29. Immunohistochemical expression of BRCA1 and lethal prostate cancer. Cancer Res. 2010 Apr 15; 70(8):3136-9.
    View in: PubMed
    Score: 0.113
  30. Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev. 2010 Feb; 19(2):484-91.
    View in: PubMed
    Score: 0.112
  31. Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol. 2009 Nov 20; 27(33):5627-33.
    View in: PubMed
    Score: 0.110
  32. Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' Health Study. J Natl Cancer Inst. 2009 Oct 21; 101(20):1406-11.
    View in: PubMed
    Score: 0.109
  33. Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study. Int J Cancer. 2009 Sep 01; 125(5):1143-6.
    View in: PubMed
    Score: 0.109
  34. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer. 2009 Jun 01; 124(11):2683-9.
    View in: PubMed
    Score: 0.107
  35. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol. 2009 Jul 20; 27(21):3459-64.
    View in: PubMed
    Score: 0.106
  36. Aberrant cytoplasmic expression of p63 and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev. 2009 Feb; 18(2):595-600.
    View in: PubMed
    Score: 0.104
  37. Season of diagnosis and prognosis in breast and prostate cancer. Cancer Causes Control. 2009 Jul; 20(5):663-70.
    View in: PubMed
    Score: 0.103
  38. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 2008 Nov; 9(11):1039-47.
    View in: PubMed
    Score: 0.102
  39. Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort. Cancer Epidemiol Biomarkers Prev. 2008 Jul; 17(7):1682-8.
    View in: PubMed
    Score: 0.100
  40. Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort. Cancer Epidemiol Biomarkers Prev. 2008 Jan; 17(1):249-51.
    View in: PubMed
    Score: 0.097
  41. Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. Lancet Public Health. 2020 09; 5(9):e475-e483.
    View in: PubMed
    Score: 0.058
  42. Risk of COVID-19 among frontline healthcare workers and the general community: a prospective cohort study. medRxiv. 2020 May 25.
    View in: PubMed
    Score: 0.057
  43. The COronavirus Pandemic Epidemiology (COPE) Consortium: A Call to Action. Cancer Epidemiol Biomarkers Prev. 2020 07; 29(7):1283-1289.
    View in: PubMed
    Score: 0.057
  44. Alcohol Intake and Risk of Lethal Prostate Cancer in the Health Professionals Follow-Up Study. J Clin Oncol. 2019 06 10; 37(17):1499-1511.
    View in: PubMed
    Score: 0.053
  45. Circulating 25-hydroxyvitamin D, vitamin D binding protein and risk of advanced and lethal prostate cancer. Int J Cancer. 2019 05 15; 144(10):2401-2407.
    View in: PubMed
    Score: 0.052
  46. Current or recent smoking is associated with more variable telomere length in prostate stromal cells and prostate cancer cells. Prostate. 2018 02; 78(3):233-238.
    View in: PubMed
    Score: 0.048
  47. Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer. Nat Commun. 2017 09 04; 8(1):420.
    View in: PubMed
    Score: 0.047
  48. Weight change, obesity and risk of prostate cancer progression among men with clinically localized prostate cancer. Int J Cancer. 2017 09 01; 141(5):933-944.
    View in: PubMed
    Score: 0.047
  49. Dairy intake in relation to prostate cancer survival. Int J Cancer. 2017 05 01; 140(9):2060-2069.
    View in: PubMed
    Score: 0.046
  50. Regular Aspirin Use and the Risk of Lethal Prostate Cancer in the Physicians' Health Study. Eur Urol. 2017 11; 72(5):821-827.
    View in: PubMed
    Score: 0.045
  51. Prognostic Utility of a New mRNA Expression Signature of Gleason Score. Clin Cancer Res. 2017 Jan 01; 23(1):81-87.
    View in: PubMed
    Score: 0.044
  52. Meat, Fish, Poultry, and Egg Intake at Diagnosis and Risk of Prostate Cancer Progression. Cancer Prev Res (Phila). 2016 Dec; 9(12):933-941.
    View in: PubMed
    Score: 0.044
  53. Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade. Cancer Causes Control. 2016 08; 27(8):1043-7.
    View in: PubMed
    Score: 0.044
  54. Common variation in BRCA1 may have a role in progression to lethal prostate cancer after radiation treatment. Prostate Cancer Prostatic Dis. 2016 06; 19(2):197-201.
    View in: PubMed
    Score: 0.043
  55. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. J Natl Cancer Inst. 2016 Feb; 108(2).
    View in: PubMed
    Score: 0.042
  56. ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3). Prostate. 2015 Nov; 75(15):1677-81.
    View in: PubMed
    Score: 0.041
  57. Physical Activity from Early Adulthood and Risk of Prostate Cancer: A 24-Year Follow-Up Study among Icelandic Men. Cancer Prev Res (Phila). 2015 Oct; 8(10):905-11.
    View in: PubMed
    Score: 0.041
  58. Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. Mol Cancer Res. 2015 Oct; 13(10):1431-40.
    View in: PubMed
    Score: 0.041
  59. Prediagnostic Obesity and Physical Inactivity Are Associated with Shorter Telomere Length in Prostate Stromal Cells. Cancer Prev Res (Phila). 2015 Aug; 8(8):737-42.
    View in: PubMed
    Score: 0.040
  60. Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues. J Mol Diagn. 2015 Jul; 17(4):374-81.
    View in: PubMed
    Score: 0.040
  61. Molecular differences in transition zone and peripheral zone prostate tumors. Carcinogenesis. 2015 Jun; 36(6):632-8.
    View in: PubMed
    Score: 0.040
  62. Asthma and risk of lethal prostate cancer in the Health Professionals Follow-Up Study. Int J Cancer. 2015 Aug 15; 137(4):949-58.
    View in: PubMed
    Score: 0.040
  63. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet. 2014 Oct; 46(10):1103-9.
    View in: PubMed
    Score: 0.038
  64. 5a-Reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern Med. 2014 Aug; 174(8):1301-7.
    View in: PubMed
    Score: 0.038
  65. RE: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst. 2014 Apr; 106(4):dju018.
    View in: PubMed
    Score: 0.037
  66. Benchmarks for operative outcomes of robotic and open radical prostatectomy: results from the Health Professionals Follow-up Study. Eur Urol. 2015 Mar; 67(3):432-8.
    View in: PubMed
    Score: 0.037
  67. Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era. J Natl Cancer Inst. 2014 Feb; 106(2):djt430.
    View in: PubMed
    Score: 0.037
  68. Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Eur Urol. 2014 Jun; 65(6):1069-75.
    View in: PubMed
    Score: 0.037
  69. Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev. 2013 Nov; 22(11):1984-93.
    View in: PubMed
    Score: 0.036
  70. Gleason grade progression is uncommon. Cancer Res. 2013 Aug 15; 73(16):5163-8.
    View in: PubMed
    Score: 0.036
  71. Prostate cancer cell telomere length variability and stromal cell telomere length as prognostic markers for metastasis and death. Cancer Discov. 2013 Oct; 3(10):1130-41.
    View in: PubMed
    Score: 0.035
  72. Sleep disruption among older men and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2013 May; 22(5):872-9.
    View in: PubMed
    Score: 0.035
  73. Consumption of fish products across the lifespan and prostate cancer risk. PLoS One. 2013; 8(4):e59799.
    View in: PubMed
    Score: 0.035
  74. Whole milk intake is associated with prostate cancer-specific mortality among U.S. male physicians. J Nutr. 2013 Feb; 143(2):189-96.
    View in: PubMed
    Score: 0.034
  75. Selenoprotein P genetic variants and mrna expression, circulating selenium, and prostate cancer risk and survival. Prostate. 2013 May; 73(7):700-5.
    View in: PubMed
    Score: 0.034
  76. Common genetic variation of the calcium-sensing receptor and lethal prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2013 Jan; 22(1):118-26.
    View in: PubMed
    Score: 0.034
  77. Rye bread consumption in early life and reduced risk of advanced prostate cancer. Cancer Causes Control. 2012 Jun; 23(6):941-50.
    View in: PubMed
    Score: 0.033
  78. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst. 2012 May 02; 104(9):690-9.
    View in: PubMed
    Score: 0.033
  79. Rye bread consumption in early life and reduced risk of advanced prostate cancer. J Clin Oncol. 2012 Feb 10; 30(5_suppl):79.
    View in: PubMed
    Score: 0.032
  80. Insomnia among elderly men and risk of prostate cancer. J Clin Oncol. 2012 Feb 10; 30(5_suppl):78.
    View in: PubMed
    Score: 0.032
  81. Milk and dairy consumption among men with prostate cancer and risk of metastases and prostate cancer death. Cancer Epidemiol Biomarkers Prev. 2012 Mar; 21(3):428-36.
    View in: PubMed
    Score: 0.032
  82. Milk intake in early life and risk of advanced prostate cancer. Am J Epidemiol. 2012 Jan 15; 175(2):144-53.
    View in: PubMed
    Score: 0.032
  83. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec; 20(12):2618-27.
    View in: PubMed
    Score: 0.031
  84. Watchful waiting and quality of life among prostate cancer survivors in the Physicians' Health Study. J Urol. 2011 Nov; 186(5):1862-7.
    View in: PubMed
    Score: 0.031
  85. a-Methylacyl-CoA racemase expression and lethal prostate cancer in the Physicians' Health Study and Health Professionals Follow-up Study. Prostate. 2012 Feb; 72(3):301-6.
    View in: PubMed
    Score: 0.031
  86. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol. 2011 Jun 10; 29(17):2378-85.
    View in: PubMed
    Score: 0.030
  87. Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PLoS One. 2011 Apr 06; 6(4):e18625.
    View in: PubMed
    Score: 0.030
  88. Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels. Carcinogenesis. 2011 Jun; 32(6):853-9.
    View in: PubMed
    Score: 0.030
  89. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature. 2011 Feb 10; 470(7333):269-73.
    View in: PubMed
    Score: 0.030
  90. Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet. 2010 Nov 11; 6(11):e1001204.
    View in: PubMed
    Score: 0.029
  91. Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev. 2010 Nov; 19(11):2869-76.
    View in: PubMed
    Score: 0.029
  92. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol. 2010 Sep 01; 28(25):3958-64.
    View in: PubMed
    Score: 0.029
  93. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet. 2010 Aug 01; 19(15):3089-101.
    View in: PubMed
    Score: 0.029
  94. A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Cancer Prev Res (Phila). 2010 May; 3(5):604-10.
    View in: PubMed
    Score: 0.028
  95. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics. 2010 Mar 16; 3:8.
    View in: PubMed
    Score: 0.028
  96. Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: cohort study in the United States. J Natl Cancer Inst. 2010 Mar 03; 102(5):307-14.
    View in: PubMed
    Score: 0.028
  97. Immediate risk for cardiovascular events and suicide following a prostate cancer diagnosis: prospective cohort study. PLoS Med. 2009 Dec; 6(12):e1000197.
    View in: PubMed
    Score: 0.028
  98. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem. 2010 Jan; 56(1):34-43.
    View in: PubMed
    Score: 0.028
  99. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res. 2009 Jul 01; 69(13):5568-74.
    View in: PubMed
    Score: 0.027
  100. Toll-like receptor signaling pathway variants and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev. 2009 Jun; 18(6):1859-63.
    View in: PubMed
    Score: 0.027
  101. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res. 2009 May 01; 15(9):3223-30.
    View in: PubMed
    Score: 0.026
  102. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst. 2009 Apr 01; 101(7):519-32.
    View in: PubMed
    Score: 0.026
  103. Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levels. Br J Cancer. 2008 Nov 18; 99(10):1743-7.
    View in: PubMed
    Score: 0.025
  104. No association between a polymorphic variant of the IRS-1 gene and prostate cancer risk. Prostate. 2008 Sep 15; 68(13):1416-20.
    View in: PubMed
    Score: 0.025
  105. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst. 2008 Jun 04; 100(11):815-25.
    View in: PubMed
    Score: 0.025
  106. Prostate cancer risk and ESR1 TA, ESR2 CA repeat polymorphisms. Cancer Epidemiol Biomarkers Prev. 2007 Nov; 16(11):2233-6.
    View in: PubMed
    Score: 0.024
  107. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med. 2007 Mar; 4(3):e103.
    View in: PubMed
    Score: 0.023
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.